Literature DB >> 12424720

Fulminant hepatic failure: outcome after listing for highly urgent liver transplantation-12 years experience in the nordic countries.

Bjørn Brandsaeter1, Krister Höckerstedt, Styrbjörn Friman, Bo-Göran Ericzon, Preben Kirkegaard, Helena Isoniemi, Michael Olausson, Ulrika Broome, Lars Schmidt, Aksel Foss, Kristian Bjøro.   

Abstract

Fulminant hepatic failure is a common indication for liver transplantation. Outcomes of patients listed for a highly urgent liver transplantation have been studied, with special emphasis on etiology of the liver disease, clinical condition, and ABO blood type. Data have been collected from the Nordic Liver Transplantation Registry. All Nordic patients listed for a highly urgent primary liver transplantation during a 12-year period have been included. Of the 315 patients listed for a highly urgent liver transplantation, 229 (73%) received a first liver allograft, 50 patients (16%) died without transplantation, and 36 patients (11%) were permanently withdrawn and survived. In 43% of the patients, no definite etiology of the liver failure could be established. Paracetamol intoxication was the most frequent specific indication for listing. Patients with blood type A had no significant shorter waiting time (3.8 v 6.6 days; P =.1) but a higher rate of transplantation (82% v 66%, P =.006) as compared with blood type O patients. In a multivariate analysis, paracetamol intoxication remained the single independent predictor of an outcome without transplantation. In conclusion, a high transplantation rate was observed among patients listed for a highly urgent liver transplantation because of fulminant hepatic failure. Blood type O patients had a lower chance of receiving a liver allograft. Patients with paracetamol intoxication had both a higher mortality without transplantation and a higher withdrawal rate attributable to improved condition.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12424720     DOI: 10.1053/jlts.2002.35556

Source DB:  PubMed          Journal:  Liver Transpl        ISSN: 1527-6465            Impact factor:   5.799


  22 in total

Review 1.  Acute liver failure and liver transplantation.

Authors:  Nobuhisa Akamatsu; Yasuhiko Sugawara; Norihiro Kokudo
Journal:  Intractable Rare Dis Res       Date:  2013-08

Review 2.  Current concepts in the diagnosis and management of autoimmune hepatitis.

Authors:  Stephen Kriese; Michael A Heneghan
Journal:  Frontline Gastroenterol       Date:  2012-11-12

Review 3.  [Acute liver failure. How much diagnostic work-up and therapy does my patient need?].

Authors:  J Hadem; A S Schneider; M P Manns
Journal:  Internist (Berl)       Date:  2011-07       Impact factor: 0.743

4.  Acute Liver Failure.

Authors:  J Eileen Hay
Journal:  Curr Treat Options Gastroenterol       Date:  2004-12

Review 5.  Etiology and management of fulminant hepatic failure.

Authors:  Javier Vaquero; Andres T Blei
Journal:  Curr Gastroenterol Rep       Date:  2003-02

6.  Clinical characteristics and corticosteroid therapy in patients with autoimmune-hepatitis-induced liver failure.

Authors:  Bing Zhu; Shao-Li You; Zhi-Hong Wan; Hong-Ling Liu; Yi-Hui Rong; Hong Zang; Shao-Jie Xin
Journal:  World J Gastroenterol       Date:  2014-06-21       Impact factor: 5.742

7.  Aetiology and outcome of acute liver failure.

Authors:  Ravi Marudanayagam; Vivekanandan Shanmugam; Bridget Gunson; Darius F Mirza; David Mayer; John Buckels; Simon R Bramhall
Journal:  HPB (Oxford)       Date:  2009-08       Impact factor: 3.647

Review 8.  Novel acetylcysteine regimens for treatment of paracetamol overdose.

Authors:  W Stephen Waring
Journal:  Ther Adv Drug Saf       Date:  2012-12

Review 9.  [Acute liver failure. Current aspects of diagnosis and therapy].

Authors:  M Bauer; M Paxian; A Kortgen
Journal:  Anaesthesist       Date:  2004-06       Impact factor: 1.041

10.  Albumin dialysis has a favorable effect on amino acid profile in hepatic encephalopathy.

Authors:  Anna-Maria Koivusalo; Taru Teikari; Krister Höckerstedt; Helena Isoniemi
Journal:  Metab Brain Dis       Date:  2008-09-05       Impact factor: 3.584

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.